Waverton Investment Management Ltd Increases Stake in Eli Lilly and Co. (LLY)
Waverton Investment Management Ltd boosted its stake in Eli Lilly and Co. (NYSE:LLY) by 134.8% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 59,289 shares of the company’s stock after buying an additional 34,038 shares during the period. Waverton Investment Management Ltd’s holdings in Eli Lilly and were worth $4,759,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors have also recently bought and sold shares of LLY. Mizuho Trust & Banking Co. Ltd. boosted its stake in shares of Eli Lilly and by 0.6% in the second quarter. Mizuho Trust & Banking Co. Ltd. now owns 1,625,795 shares of the company’s stock worth $128,031,000 after buying an additional 10,250 shares during the period. Mason Street Advisors LLC bought a new stake in shares of Eli Lilly and during the second quarter worth about $10,304,000. RNC Capital Management LLC boosted its stake in shares of Eli Lilly and by 42.4% in the second quarter. RNC Capital Management LLC now owns 410,784 shares of the company’s stock worth $32,349,000 after buying an additional 122,237 shares during the period. Zacks Investment Management boosted its stake in shares of Eli Lilly and by 2.5% in the second quarter. Zacks Investment Management now owns 186,823 shares of the company’s stock worth $14,712,000 after buying an additional 4,585 shares during the period. Finally, Private Capital Advisors Inc. bought a new stake in shares of Eli Lilly and during the second quarter worth about $28,535,000. Institutional investors own 73.93% of the company’s stock.
Shares of Eli Lilly and Co. (NYSE:LLY) traded down 0.07% during midday trading on Tuesday, hitting $67.15. The stock had a trading volume of 8,929,975 shares. Eli Lilly and Co. has a 52-week low of $64.18 and a 52-week high of $88.16. The company’s 50 day moving average is $76.26 and its 200 day moving average is $77.88. The company has a market cap of $71.02 billion, a PE ratio of 29.21 and a beta of 0.28.
Eli Lilly and (NYSE:LLY) last posted its earnings results on Tuesday, October 25th. The company reported $0.88 EPS for the quarter, missing analysts’ consensus estimates of $0.96 by $0.08. The firm earned $5.19 billion during the quarter, compared to analysts’ expectations of $4.23 billion. Eli Lilly and had a return on equity of 23.71% and a net margin of 11.73%. Eli Lilly and’s quarterly revenue was up 4.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.89 earnings per share. On average, analysts anticipate that Eli Lilly and Co. will post $3.55 earnings per share for the current year.
The company also recently announced a quarterly dividend, which will be paid on Friday, December 9th. Investors of record on Tuesday, November 15th will be given a $0.51 dividend. The ex-dividend date of this dividend is Thursday, November 10th. This represents a $2.04 dividend on an annualized basis and a dividend yield of 3.04%. Eli Lilly and’s dividend payout ratio is currently 88.70%.
ILLEGAL ACTIVITY NOTICE: This article was originally published by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are reading this article on another website, it was stolen and reposted in violation of U.S. and international copyright law. The original version of this article can be viewed at https://www.thecerbatgem.com/2016/11/29/waverton-investment-management-ltd-increases-stake-in-eli-lilly-and-co-lly.html.
A number of analysts recently issued reports on LLY shares. Goldman Sachs Group Inc. raised Eli Lilly and from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $89.00 to $95.00 in a report on Tuesday, September 27th. Morgan Stanley set a $73.00 price objective on Eli Lilly and and gave the stock a “hold” rating in a report on Thursday, November 24th. Zacks Investment Research cut Eli Lilly and from a “buy” rating to a “hold” rating in a report on Thursday, August 4th. Jefferies Group reissued a “buy” rating and set a $105.00 price objective on shares of Eli Lilly and in a report on Wednesday, September 14th. Finally, Argus increased their price objective on Eli Lilly and from $90.00 to $95.00 and gave the stock a “buy” rating in a report on Tuesday, August 2nd. Four analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $108.34.
In related news, insider Maria A. Crowe sold 2,248 shares of the business’s stock in a transaction dated Wednesday, October 5th. The stock was sold at an average price of $81.37, for a total value of $182,919.76. Following the sale, the insider now directly owns 94,319 shares in the company, valued at $7,674,737.03. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.20% of the stock is owned by corporate insiders.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Stock Ratings for Eli Lilly and Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Co. and related stocks with our FREE daily email newsletter.